p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer

[1]  P. Park,et al.  Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Isaacs,et al.  Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer , 2017, Clinical Cancer Research.

[3]  K. Pienta,et al.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[5]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[6]  E. Antonarakis,et al.  Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration‐Resistant Prostate Cancer: A Retrospective Study , 2017, The Prostate.

[7]  M. Gleave,et al.  Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC). , 2016 .

[8]  Joshua M. Stuart,et al.  Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). , 2016 .

[9]  P. Carroll,et al.  Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison to PTEN FISH , 2016, Modern Pathology.

[10]  Hamid Bolouri,et al.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer , 2016 .

[11]  G. Scagliotti,et al.  Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. , 2015, Cancer treatment reviews.

[12]  K. Baggerly,et al.  Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers , 2015, Clinical Cancer Research.

[13]  E. Antonarakis,et al.  Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer , 2015, The Prostate.

[14]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[15]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[16]  E. Antonarakis,et al.  Androgen pathway resistance in prostate cancer and therapeutic implications , 2015, Expert opinion on pharmacotherapy.

[17]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[18]  Michael Kerger,et al.  Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer , 2015, Nature Communications.

[19]  D. Dearnaley,et al.  PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate , 2015, European urology.

[20]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[21]  Martin E. Gleave,et al.  Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[22]  M. Loda,et al.  Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors , 2014, Clinical Cancer Research.

[23]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[24]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[25]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[26]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[27]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[28]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[29]  V. Arora,et al.  Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.

[30]  I. Shih,et al.  TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high‐grade serous carcinoma—evidence supporting the clonal relationship of the two lesions , 2012, The Journal of pathology.

[31]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[32]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[33]  L. Tran,et al.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. , 2011, Cancer cell.

[34]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[35]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Shunyou Wang,et al.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.

[37]  J. Moul,et al.  p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  P. Troncoso,et al.  Frequency and characterization of p53 mutations in clinically localized prostate cancer. , 1995, Urology.

[39]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[40]  A. Levine,et al.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation , 1989, Journal of virology.